Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 3
1975 4
1976 4
1977 2
1978 1
1979 5
1980 4
1981 7
1982 2
1983 8
1984 3
1986 4
1987 5
1988 4
1989 3
1990 1
1991 5
1992 10
1993 11
1994 5
1995 6
1996 8
1997 11
1998 16
1999 17
2000 16
2001 21
2002 20
2003 18
2004 23
2005 26
2006 23
2007 23
2008 26
2009 29
2010 22
2011 32
2012 25
2013 32
2014 39
2015 33
2016 37
2017 34
2018 33
2019 37
2020 39
2021 50
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

738 results
Results by year
Filters applied: . Clear all
Page 1
Orthostatic hypotension: A review.
Joseph A, Wanono R, Flamant M, Vidal-Petiot E. Joseph A, et al. Nephrol Ther. 2017 Apr;13 Suppl 1:S55-S67. doi: 10.1016/j.nephro.2017.01.003. Nephrol Ther. 2017. PMID: 28577744 Review.
Pharmacological treatment may sometimes be necessary and mainly relies on volume expansion by fludrocortisone and/or a vasopressor agents such as midodrine. There is no predefined blood pressure target, the goal of therapy being the relief of symptoms and fall prevention.. …
Pharmacological treatment may sometimes be necessary and mainly relies on volume expansion by fludrocortisone and/or a vasopressor agents su …
Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial.
Santer P, Anstey MH, Patrocínio MD, Wibrow B, Teja B, Shay D, Shaefi S, Parsons CS, Houle TT, Eikermann M; MIDAS Study Group. Santer P, et al. Intensive Care Med. 2020 Oct;46(10):1884-1893. doi: 10.1007/s00134-020-06216-x. Epub 2020 Sep 3. Intensive Care Med. 2020. PMID: 32885276 Free PMC article. Clinical Trial.
Time to vasopressor discontinuation was not different between midodrine and placebo groups (median [IQR], 23.5 [10-54] vs 22.5 [10.4-40] h; difference, 1 h; 95% CI - 10.4 to 12.3 h; p = 0.62). No differences in secondary endpoints were observed. Bradycardia occurred more o …
Time to vasopressor discontinuation was not different between midodrine and placebo groups (median [IQR], 23.5 [10-54] vs 22.5 [10.4- …
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Cavallin M, et al. Hepatology. 2015 Aug;62(2):567-74. doi: 10.1002/hep.27709. Epub 2015 Feb 13. Hepatology. 2015. PMID: 25644760 Free article. Clinical Trial.
Where terlipressin is not available, as in the United States, midodrine and octreotide with albumin are used as an alternative treatment of HRS. ...CONCLUSION: Terlipressin plus albumin is significantly more effective than midodrine and octreotide plus albumin in im …
Where terlipressin is not available, as in the United States, midodrine and octreotide with albumin are used as an alternative treatm …
Catecholamine Vasopressor Support Sparing Strategies in Vasodilatory Shock.
Buckley MS, Barletta JF, Smithburger PL, Radosevich JJ, Kane-Gill SL. Buckley MS, et al. Pharmacotherapy. 2019 Mar;39(3):382-398. doi: 10.1002/phar.2199. Epub 2019 Jan 2. Pharmacotherapy. 2019. PMID: 30506565 Review.
Adjunctive therapeutic options to reduce vasoactive support requirements without compromising arterial pressure include arginine vasopressin and analogs, corticosteroids, midodrine, methylene blue, and angiotensin II. Although concomitant vasopressin and corticosteroids ha …
Adjunctive therapeutic options to reduce vasoactive support requirements without compromising arterial pressure include arginine vasopressin …
Midodrine for the weaning of vasopressor infusions.
Poveromo LB, Michalets EL, Sutherland SE. Poveromo LB, et al. J Clin Pharm Ther. 2016 Jun;41(3):260-5. doi: 10.1111/jcpt.12375. Epub 2016 Mar 4. J Clin Pharm Ther. 2016. PMID: 26945564
RESULTS AND DISCUSSION: The analysis included 188 patients (94 midodrine and 94 control). Patients discontinued IV vasopressors a median of 12 days (IQR 05-28) after midodrine initiation. ...Adverse event rates after midodrine use were consistent with those o …
RESULTS AND DISCUSSION: The analysis included 188 patients (94 midodrine and 94 control). Patients discontinued IV vasopressors a med …
Orthostatic hypotension for the cardiologist.
Mar PL, Raj SR. Mar PL, et al. Curr Opin Cardiol. 2018 Jan;33(1):66-72. doi: 10.1097/HCO.0000000000000467. Curr Opin Cardiol. 2018. PMID: 28984649 Free PMC article. Review.
This represents only the second drug approved by the FDA for orthostatic hypotension, the first being midodrine in 1986. A handful of smaller head-to-head studies have pitted not only pharmacologic agents to one another but also nonpharmacologic interventions to pharmacolo …
This represents only the second drug approved by the FDA for orthostatic hypotension, the first being midodrine in 1986. A handful of …
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.
Solà E, Solé C, Simón-Talero M, Martín-Llahí M, Castellote J, Garcia-Martínez R, Moreira R, Torrens M, Márquez F, Fabrellas N, de Prada G, Huelin P, Lopez Benaiges E, Ventura M, Manríquez M, Nazar A, Ariza X, Suñé P, Graupera I, Pose E, Colmenero J, Pavesi M, Guevara M, Navasa M, Xiol X, Córdoba J, Vargas V, Ginès P. Solà E, et al. J Hepatol. 2018 Dec;69(6):1250-1259. doi: 10.1016/j.jhep.2018.08.006. Epub 2018 Aug 21. J Hepatol. 2018. PMID: 30138685 Clinical Trial.
The aim of this study was to investigate whether treatment with midodrine, an alpha-adrenergic vasoconstrictor, together with intravenous albumin improves circulatory dysfunction and prevents complications of cirrhosis in patients awaiting LT. ...This study was aimed at in …
The aim of this study was to investigate whether treatment with midodrine, an alpha-adrenergic vasoconstrictor, together with intrave …
Orthostatic hypotension in the elderly: diagnosis and treatment.
Gupta V, Lipsitz LA. Gupta V, et al. Am J Med. 2007 Oct;120(10):841-7. doi: 10.1016/j.amjmed.2007.02.023. Am J Med. 2007. PMID: 17904451 Review.
If these measures prove inadequate and the patient remains persistently symptomatic, various pharmacotherapeutic agents can be added, including fludrocortisone, midodrine, and nonsteroidal anti-inflammatory drugs. The goals of treatment are to improve symptoms and to make …
If these measures prove inadequate and the patient remains persistently symptomatic, various pharmacotherapeutic agents can be added, includ …
Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL. Israelsen M, et al. Cochrane Database Syst Rev. 2017 Sep 27;9(9):CD011532. doi: 10.1002/14651858.CD011532.pub2. Cochrane Database Syst Rev. 2017. PMID: 28953318 Free PMC article. Review.
The trials compared terlipressin versus noradrenaline (seven trials), octreotide (one trial), midodrine and octreotide (one trial), or dopamine (one trial). All participants in both groups received albumin as cointervention. ...Considering reversal of hepatorenal syndrome, …
The trials compared terlipressin versus noradrenaline (seven trials), octreotide (one trial), midodrine and octreotide (one trial), o …
Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A, Chandar AK, Murad MH, Prokop LJ, Muscatiello N, Kamath PS, Singh S. Facciorusso A, et al. Lancet Gastroenterol Hepatol. 2017 Feb;2(2):94-102. doi: 10.1016/S2468-1253(16)30157-1. Epub 2016 Dec 2. Lancet Gastroenterol Hepatol. 2017. PMID: 28403995 Review.
Moderate-quality evidence supported the use of terlipressin over midodrine plus octreotide (OR 2625, 95% CI 307-22421) to reverse hepatorenal syndrome, with low-quality evidence supporting the use of noradrenaline over placebo (417, 137-1250) and over midodrine plus …
Moderate-quality evidence supported the use of terlipressin over midodrine plus octreotide (OR 2625, 95% CI 307-22421) to reverse hep …
738 results